Interim guidance for clinicians to prioritize antiviral treatment of influenza in the setting of reduced availability of oseltamivir

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Distributed via the CDC Health Alert Network December 14, 2022, 4:00 PM ET CDCHAN-00482
  
  Seasonal influenza activity is high across the United States. The Centers for Disease Control and Prevention (CDC) estimates that in the 2022-2023 season to date, there have been at least 13 million illnesses, 120,000 hospitalizations, and 7,300 deaths from influenza (Weekly U.S. Influenza Surveillance Report | CDC). While the Food and Drug Administration (FDA) has not indicated shortages of oseltamivir (generic or Tamiflu) in any of its forms (capsules, oral suspension), CDC has received numerous anecdotal reports of availability issues for generic oseltamivir in some locations [1]. This may continue to occur in some communities as influenza activity continues.
  
  This Health Alert Network (HAN) Health Advisory provides clinicians and public health officials with guidance for prioritizing oseltamivir for treatment and information on other influenza antivirals that are recommended for treating influenza in areas where oseltamivir is temporarily unavailable.
  
  
• Subjects:
  Antiviral Agents Disease Outbreaks Influenza, Human/drug Therapy Oseltamivir/supply & Distribution
• Source:
  HAN ; 482
• Series:
  Health Alert Network
• Document Type:
  HAN Health Advisory
• Name as Subject:
  Oseltamivir ; Oseltamivir
• Issue:
  482
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:d4d98c4690b397a23cdb2d8a58edb3644b745dddfee7769525c992124a08f7fc67a3a370a04ae78566424580509448dfce8c5d17074df77b8ed6fa46a9c5b533
• Download URL:
  https://stacks.cdc.gov/view/cdc/122761/cdc_122761_DS1.pdf
• File Type:
  [PDF - 167.08 KB ]